TriLink BioTechnologies社 Thermostable RNA Vaccine Delivery Promises Enhanced Pandemic Response
Thermostable RNA Vaccine Delivery Promises Enhanced Pandemic Response
|
RNA-based vaccines offer several advantages over traditional ones, including faster production, simpler scale-up, and more rapid adaptability to new targets. These factors have proven critical in tackling the ongoing COVID-19 pandemic, allowing vaccines targeting SARS-CoV-2 to be developed in record time, while also enabling the rapid evolution of vaccination strategies as new strains of the virus emerge. Both Pfizer/BioNTech and Moderna received regulatory approval for their mRNA vaccine products within a year of the novel coronavirus first being sequenced, and many more RNA vaccines are currently in clinical trials...
![Read_More_FOI.PNG](/Fount/Read_More_FOI.PNG_3.png)
Your partner for mRNA vaccine development
The recent clinical success of mRNA vaccines against SARS-CoV-2 paves the way for future vaccine development. Whether you are in the discovery phase or nearing GMP manufacturing, TriLink offers a solution to fit your mRNA vaccine program:
|
· Plasmid manufacturing for use as an IVT template
· Custom mRNA synthesis from RUO through GMP grade
· CleanCap® capping technology for non-replicating mRNA and self-amplifying mRNA
Learn more about how TriLink can support your vaccine development program.
|
![mRNA Vaccine Solutions.PNG](/Fount/mRNA%20Vaccine%20Solutions.PNG) |
![Learn_More_FOI.PNG](/Fount/Learn_More_FOI.PNG_1.png) |
Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。
![](/source/img/common/pagetop.png)